Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

SAT0196 An assessment of impairment of productivity among SLE patients:

(2014) M. Schneider et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

(2012) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus

(2011) V. STRAND et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Measuring outcomes in systemic lupus erythematosus clinical trials

(2011) Vibeke Strand et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study

(2010) K. McElhone et al.   LUPUS

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases

(2009) V Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

(2009) Michael P. Cancro et al.   JOURNAL OF CLINICAL INVESTIGATION

The socioeconomic burden of SLE

(2009) Chak Sing Lau et al.   Nature Reviews Rheumatology

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: Mortality risk and quality of life early in the course of disease

(2008) Robert Campbell et al.   ARTHRITIS AND RHEUMATISM

Deriving an Algorithm to Convert the Eight Mean SF-36 Dimension Scores into a Mean EQ-5D Preference-Based Score from Published Studies (Where Patient Level Data Are Not Available)

(2008) Roberta Ara et al.   VALUE IN HEALTH